Skip to main content
. Author manuscript; available in PMC: 2021 May 14.
Published in final edited form as: J Med Chem. 2020 Apr 17;63(9):4528–4554. doi: 10.1021/acs.jmedchem.9b01573

Table 5.

Effective Permeability (Pe) of Five Commercial Drugs and nNOS Inhibitors in the PAMPA–BBB Assaya

Compd log Db log Pb TPSA (Å2)c reported Pe (10−6 cm s−1)d determined Pe (10−6 cm s−1)e BBB permeant predictionc prediction
verapamil 2.29 4.55 63.95 16 21.3 ± 1.5f 18.5 ± 1.9 BBB (+) CNS (+)
chlorpromazine 2.76 4.56 31.78 6.5 8.04 ± 0.41f 8.90 ± 0.68 BBB (+) CNS (+)
dopamine −1.50 0.03 66.48 0.2 0.12 ± 0.41f 0.125 ± 0.14 BBB (−) CNS (−)
7 1.36 3.32 64.93 11.3 ± 1.64 BBB (+) CNS (+)
12 1.27 3.18 64.93 15.5 ± 2.32 BBB (+) CNS (+)
29 2.37 3.78 74.16 14.6 ± 0.97 BBB (+) CNS (+)
33 2.13 3.53 87.05 8.09 ± 0.67 BBB (−) CNS (+)
37 1.94 3.35 115.29 7.04 ± 2.43 BBB (−) CNS (+)
a

All assays were performed over 17 h at a concentration of 200 μM; see Experimental Section for details.

b

Log D (pH = 7.4) and log P values of the free-base species were predicted using ChemAxon software.

c

TPSA calculations and BBB permeation was predicted using the free web tool SwissADME.

d

Effective permeability values from literature.32

e

Effective permeability values obtained in-house.

f

Experimental Pe values reported previously by Do et al.68

HHS Vulnerability Disclosure